No Data
Everbright: Import substitution is expected to accelerate, pay attention to the rising market share of domestic surgical robots.
Everbright stated that the import substitution is expected to accelerate, paying attention to the rise in market share of domestic surgical robots.
China Securities Co.,Ltd.: It is recommended to focus on the new growth and integration opportunities in the Industry.
China Securities Co.,Ltd. remains bullish on high-quality Innovative Drugs companies in 2025 and actively focuses on cutting-edge technologies in pharmaceuticals and medical devices.
In the "Performance" report, MicroTech Medical (02235.HK) reduced its annual loss to 63.12 million yuan.
Microtech Medical - B (02235.HK) announced its performance for the fiscal year 2024, with revenue of 0.346 billion yuan, an increase of 36.5% year-on-year. The loss narrowed from 0.125 billion yuan in the previous year to 63.12 million yuan, with a loss per share of 15 cents. No final dividend will be distributed.
MicroTech Medical-B (02235) announces annual performance, with a gross profit of 0.183 billion yuan, a year-on-year increase of 51.5%.
MicroTech Medical-B (02235) announced its annual performance results for the year ending December 31, 2024, with revenue of 3.4...
MICROTECH MED-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024
Zhitong Hong Kong Stock Investment Log | March 28
Hong Kong Stock Investment Log | March 28, 2025
